Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 12, 2007, Pages 1429-1434

  Zullo, A ^a   Perna, F ^b   Hassan, C ^a   Ricci, C ^c   Saracino, I ^b   Morini, S ^a   Vaira, D ^b  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DYSPEPSIA; FEMALE; HELICOBACTER PYLORI; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PEPTIC ULCER; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OFLOXACIN; TREATMENT OUTCOME;

EID: 34249789842     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03331.x     Document Type: Article

References (39)

1. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002 16 : 1269 75.
2. Maconi G, Tosetti C, Miroglio G, et al. Management of Helicobacter pylori-related gastrointestinal diseases by general practitioners in Italy. Aliment Pharmacol Ther 1999 13 : 1499 504.
3. Sharma VK, Howden CW. A national survey of primary care physicians' perceptions and practices related to Helicobater pylori infection. J Clin Gastroenterol 2004 38 : 326 31.
4. Shirin H, Birkenfeld S, Shevah O, et al. Application of Maastricht 2-2000 guidelines for the management of Helicobacter pylori among specialists and primary care physicians in Israel: are we missing the malignant potential of Helicobacter pylori? J Clin Gastroenterol 2004 38 : 322 5.
5. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004 53 : 1374 84.
6. Koletzko S, Richy F, Bontems P, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006 55 : 1811 6.
7. Houben M, van de Beek D, Hensen E, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999 13 : 1047 55.
8. De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004 19 : 407 14.
9. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 1339 43.
10. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005 22 : 45 9.
11. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003 35 : 232.
12. Gisbert JP, De La Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006 23 : 35 44.
13. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy vs. bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006 101 : 488 96.
14. Perna F, Gatta L, Figura N, et al. Susceptibility of Helicobacter pylori to metronidazole. Am J Gastroenterol 2003 98 : 2157 61.
15. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolone in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006 11 : 441 5.
16. Laheij RJ, Van Rossum LGM, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999 13 : 857 64.
17. Janssen MJR, Van Oijen AHAM, Verbeek ALM, Jansen JBMJ, de Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxycillin or a nitroimidazole. Aliment Pharmacol Ther 2001 15 : 613 24.
18. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of one and two weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER study. Gut 2006 56 : 475 9.
19. Paoluzi P, Iacopini F, Crispino P, et al. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter 2006 11 : 562 8.
20. De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Int Med 2006 144 : 94 100.
21. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2006 Epub ahead of print A, Rassu M, Leandro G, Franceschi M, Di Mario F. Prevalence of Helicobacter pylori resistance to antibiotic in northeast Italy: a multicentre study. Dig Liver Dis 2000 32 : 763 8.
22. Savarino V, Zentilin P, Pivari M, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000 14 : 893 900.
23. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001 15 : 1023 9.
24. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003 35 : 541 5.
25. De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007 59 : 783 5.
26. Huang JQ, Zheng GF, Hunt RH, et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol 2005 11 : 2726 32.
27. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003 17 : 719 26.
28. Zullo A, Gatta L, De Francesco V, et al. High Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 2005 22 : 1419 24.
29. Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2006 129 : 1414 19.
30. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin-based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003 35 : 711.
31. Coelho LG, Moretzsohn LD, Vieira WL, et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 2005 21 : 783 7.
32. Wong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006 23 : 421 7.
33. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006 28 : 6 13.
34. Glocker E, Stueger H-P, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007 51 : 346 9.
35. Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004 19 : 789 95.
36. Wang G, Taylor DE. Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two type resistance to Macrolide-Lincosamide- Streptogramin B antibiotics. J Antimicrob Chemother 1998 42 : 1952 8.
37. Han F, Liu S, Ho B, Yan Z, Yan X. Alterations in rdxA and frxA genes and their upstream regions in metronidazole-resistant Helicobacter pylori isolates. Res Microbiol 2007 158 : 38 44.
38. Osato MS, Reddy SG, Piergies AA, Bochenek WJ, Testa RT, Graham DY. Compared efficacy of new investigational agents against Helicobacter pylori. Aliment Pharmacol Ther 2001 15 : 487 92.
39. Cattoir V, Nectoux J, Lascols C, et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hyper susceptibility. Int J Antimicrobial Agents 2007 29 : 389 96.